Cell 2017-07-13

IL-4Rα Inhibitor for Atopic Disease

Howard Y. Chang, Kari C. Nadeau

Index: 10.1016/j.cell.2017.06.046

Full Text: HTML

Abstract

Dupilumab is a fully human IgG4 monoclonal antibody directed against the IL-4Rα subunit of IL-4 and IL-13 receptors. It blocks the signaling pathways of IL-4 and IL-13, key cytokines that drive type 2 inflammatory response. In March 2017, dupilumab was approved for use in the treatment of atopic dermatitis (eczema). To view this Bench to Bedside, open or download the PDF.

Latest Articles:

Unshielding Exosomal RNA Unleashes Tumor Growth And Metastasis

2017-07-13

[10.1016/j.cell.2017.06.047]

Retraction Notice to: Vulnerability of Glioblastoma Cells to Catastrophic Vacuolization and Death Induced by a Small Molecule

2017-07-13

[10.1016/j.cell.2017.06.044]

Biology Gone Wild

2017-07-13

[10.1016/j.cell.2017.06.043]

Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease

2017-07-13

[10.1016/j.cell.2017.06.040]

Profiling Ssb-Nascent Chain Interactions Reveals Principles of Hsp70-Assisted Folding

2017-07-13

[10.1016/j.cell.2017.06.038]

More Articles...